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ABSTRACT
To discover new regulatory pathways in B lymphoma cells, we performed a 
combined analysis of experimental, clinical and global gene expression data. We 
identified a specific cluster of genes that was coherently expressed in primary 
lymphoma samples and suppressed by activation of the B cell receptor (BCR) through 
αIgM treatment of lymphoma cells in vitro. This gene cluster, which we called BCR.1, 
includes numerous cell cycle regulators. A reduced expression of BCR.1 genes after 
BCR activation was observed in different cell lines and also in CD10+ germinal center 
B cells. We found that BCR activation led to a delayed entry to and progression of 
mitosis and defects in metaphase. Cytogenetic changes were detected upon long-term 
αIgM treatment. Furthermore, an inverse correlation of BCR.1 genes with c-Myc co-
regulated genes in distinct groups of lymphoma patients was observed. Finally, we 
showed that the BCR.1 index discriminates activated B cell-like and germinal centre 
B cell-like diffuse large B cell lymphoma supporting the functional relevance of this 
new regulatory circuit and the power of guided clustering for biomarker discovery.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL), the 
most common lymphoid malignancy in adults, is 
derived from germinal centre or post-germinal centre 
B cells [1]. DLBCLs are clinically and molecular 
heterogenous [1-4]. Long-term disease-free survival 
is now a reality for at least 50 percent of patients. 
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However, approximately 30 percent of patients with 
DLBCL, mainly those with advanced disease and 
those who relapse, will not respond appropriately to 
current treatments [4, 5]. A better understanding of the 
specific pathways underlying the malignant phenotype 
in DLBCL is urgently required. This would allow not 
only the development of novel targeted therapeutic 
approaches for defined subgroups of DLBCL, but also 
the identification of new biomarkers [6].
Activation of B lymphocytes is associated with 
rapid proliferation, somatic hypermutation and targeted 
DNA double strand breaks in the immunoglobulin (Ig) 
locus. This process is under tight spatial and temporal 
control achieved by extracellular signals sensed via B 
cell receptor (BCR), CD40, Toll-like receptors (TLR), 
B-cell activating factor (BAFF) receptor, interleukin-21 
(IL21) receptor and cell intrinsic mechanisms [1, 7-13]. 
Molecular signatures suggest that specific signaling 
networks and survival mechanisms exist in DLBCL, 
caused either by extracellular signals from the lymphoma 
microenvironment or related pathway mutations within the 
lymphoma cells, or both [1, 13].
Based on the cell of origin two main molecularly 
defined subgroups of DLBCLs can be described: activated 
B cell (ABC) - like and germinal centre B cell (GCB) – like 
DLBCL [14]. This cell-of-origin-approach is driven by class 
labels. In parallel, signatures such as stroma, host response, 
OxPhos and BCR/proliferation or Jak/STAT and IKK have 
been described by comprehensive consensus clustering, 
and identify the lymphoma microenvironment as a defining 
feature [15-19]. The level of c-Myc activity also allows the 
subdivision of DLBCL [20-23]; a high c-Myc index or a 
high number of Myc positive lymphoma cells is associated 
with shorter survival [20-23], but the subentities defined by 
Myc expression only partly overlap with the ABC/GCB-
like signatures. Although these studies predict activity of 
different oncogenic pathways for DLBCL subtypes the 
functional consequences of differential gene expression are 
still poorly understood [15, 18, 19, 24-27],
Recently we introduced guided clustering as a 
strategy that integrates experimental, clinical and global 
gene expression data to investigate aggressive non-
Hodgkin lymphoma (NHL) [28-30]. This approach does 
not utilize the class labels from the clinical data (e.g. 
disease types or clinical outcomes) to derive a molecular 
signature, but instead is based on the underlying biology 
for example the activity of an entire pathway or pathway 
networks established by cell perturbation experiments. 
For example, in our recent proof of principle analysis 
we were able to captured quantitatively a link between 
BCL-6 gene regulation and TLR signaling. The combined 
analysis of experimental and global gene expression data 
can allow the development of functional hypotheses 
[29, 31]. Therefore, transcriptional modules (groups of 
coherent expressed genes) can be described as potential 
major oncogenic hubs that are conserved between patients.
The present study aimed to extract functional 
information on oncogenic pathway activities in 
distinct DLBCL cases based on gene expression from 
primary tumours and multiple in vitro interventions. 
To do this the guided clustering-driven identification of 
transcriptional modules was extended and multiple single 
in vitro interventions were combined in silico to identify 
transcriptional modules conserved between patients 
but dominantly affected by for example BCR signaling 
but not TLR, IL21, CD40L or BAFF. This is to enable 
the assessment of pathway specific activities in primary 
lymphoma cases.
A new regulatory circuit in B cells was identified. 
A group of dominantly suppressed genes upon BCR 
activation is involved in an overall diminished capacity of 
the cells to enter mitosis, leading to defects in metaphase 
as well as increased chromosomal aberrations. In a 
subgroup of GCB-like DLBCL with low Myc activity this 
new regulatory circuit is dominant. This regulatory circuit 
is nearly absent in BL but active in c-Mychigh DLBCLs. 
Our data supports the view that BCR signaling is context 
dependent and capable not only of promoting cell survival 
and proliferation but also delaying cell cycle progression 
thereby potentially increasing chromosomal aberrations. 
It further underpins the notion that defined pathways 
stimulated by microenvironmental factors activating the 
BCR are involved in DLBCL development and that these 
pathways might be of therapeutic relevance. Our analysis 
shows how guided clustering lead to the discovery of 
biomarkers for cancer stratification.
RESULTS
A combined analysis of experimental and 
tumour derived global gene expression data 
identifies a set of genes specifically suppressed by 
BCR activation
Ligands activating pattern recognition receptors, 
BCR, CD40, BAFF-receptors and IL21 receptor are well 
known mediators of signalling in B cells and important 
components of the GC B cell reaction. Furthermore, it is 
well known that elements of the corresponding signalling 
pathways are mutated in DLBCL [1, 7-13]. Thus, the 
signalling pathways activated by these factors represent 
promising candidates for the identification of oncogenic 
pathway signatures in DLBCL via guided clustering. To 
answer these questions, as a model cell line, BL2 was 
chosen. The criteria for their selection were: absence 
or low pathway activity, a strong signal induction by 
stimuli, and measurable global gene expression changes 
suitable for bioinformatic analysis as we have previously 
described [32].
Microarray data sets obtained from human 
transformed germinal centre B cells (BL2) stimulated 
with CD40L, BAFF, IL21, αIgM F(ab)2 fragments and 
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lipopolysaccharide (LPS) were processed as described 
previously, combined, and analysed by guided clustering 
using large-scale gene expression data from 175 DLBCL 
patients [28, 32]. The patients were selected from the 
MMML-cohort and are representative of non-mBLs 
without chromosomal MYC translocations [30]. Guided 
clustering was performed in the following way: the 
guiding datasets were obtained from in vitro stimulated 
BL2 cells and only genes driven dominantly by one 
stimuli, but not the others, included. These data sets 
were integrated with gene expression profiles of primary 
lymphoma material. Ten different gene clusters were 
identified characterized by increased or suppressed gene 
expression in experiments and concordantly expressed 
in lymphoma patients: CD40.1, CD40.2, IL21.1, IL21.2, 
BAFF.1, BAFF.2, BCR.1, BCR.2, LPS.1 and LPS.2 
(Figure 1A, Table I). The suffix “.1” denotes genes mainly 
suppressed and “.2” those genes mainly activated (Table I, 
Supplementary Table S1). These clusters most likely 
represent surrogates of pathway activity dominated by one 
of the stimuli. To delineate so far undescribed biological 
outcomes the following experiments were focused on 
αIgM driven suppression of gene expression.
Next the 137 DLBCL patient samples used for 
guided clustering were sorted according to an individual 
index value derived from BCR.1. This index reflects the 
extent to which BCR.1 genes are expressed within an 
individual sample. A high BCR.1 index indicates strong 
down-regulation of the BCR.1 genes. Finally, lymphoma 
samples were sorted according to their individual index 
(Figure 1B). This results in a spectrum of lymphoma 
samples ranging from low to high BCR.1 index scores. 
A substantial number of analysed patient samples is 
characterized by a corresponding strong BCR.1 signal.
Molecular functions, biological processes, cellular 
components and pathways of BCR.1 genes were identified 
by gene ontology (GO) based gene set enrichment 
analyses (Table II, Supplementary Table S2). Among the 
top 100 BCR.1 genes, the most significantly enriched 
gene sets corresponded to biological processes which 
included cell cycle checkpoints, microtubule-based 
processes, microtubule cytoskeleton organization, spindle 
organization, mitotic chromosome segregation or sister 
chromatid segregation as well as response to DNA damage 
stimuli, organelle organization or metabolic processes 
(Table II). In Figure 1C BCR.1 index genes associated 
with cell cycle regulatory functions are presented. Genes 
are grouped according to the corresponding cell cycle 
phases in which they are involved, demonstrating that 
more than 40% of cell cycle regulatory genes within this 
gene cluster belong to G2 and M cell cycle regulation.
Verification and validation of gene expression 
after αIgM treatment reveals the downregulation 
of BCR.1 index genes
Table III summarises the fold changes in expression 
of genes from the BCR.1 cluster involved in cell cycle 
regulation that were suppressed by αIgM treatment of 
BL2 cells.
Figure 1: Guided Clustering identifies gene clusters dominantly affected by one specific intervention. A. Heatmap 
representation of the gene expression levels for the genes within the ten transcriptional modules identified by guided clustering analysis. 
Global gene expression of stimulated BL2 cells and gene expression profiles from 175 lymphoma patients without Myc-translocations 
[28, 30]. BL2 cells treated with αIgM treatment, CD40L, LPS, BAFF and IL21. Each column in the heatmap represents a gene and each 
row represents a microarray sample. Yellow and blue indicate high and low gene expression. Heatmap shows the gene expression of the 
corresponding cluster genes in stimulated BL2 cells compared to unstimulated cells. B. A heatmap representation of BCR.1 genes in gene 
expression profiles of 137 primary lymphoma. The patient samples are ordered according to their increasing BCR.1 index starting with the 
lowest index on the very left end of the heatmap [30]. C. Gene ontology based analysis of the fraction of genes from the BCR.1 gene cluster 
associated with the cell cycle. GO Term analysis gives frequency of BCR.1 genes involved in different cell cycle phases (information taken 
from www.cyclebase.org)(for additional details see also Supplementary Table S2).
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Of the 288 genes comprising the BCR.1 index 
PLK1, AURKA, NEK2, BUB1B, CDC20, MPS1, BIRC5, 
HMMR, TACC3 and KIF14A were selected for validation 
and verification experiments by qRT-PCR in two 
independent cell lines [33-40]. These genes were selected 
because they are mitotic entry and progression regulating 
genes. BL2 and Ramos cells were stimulated with αIgM 
for 3hrs and gene expression changes analysed by qRT-
PCR (Figure 2A). In line with our microarray data, qRT-
PCR analyses show suppression of all selected BCR.1 
genes by BCR activation. Furthermore, the expression 
of these genes was analysed over time following αIgM 
treatment (Figure 2B). Data were taken from a global gene 
expression analysis in BL2 cells. Cells were stimulated 
by αIgM and harvested at different time points starting 
from 30 min after adding αIgM until 480 min. RNA of 
three independent biological experiments was hybridized 
to Human ST1.0 microarrays. Most of the genes show 
a comparable time dependent suppression after αIgM 
treatment within the first 3-5hrs. Interestingly, some of 
the genes started to return to their basal expression level 
within 8hrs, suggesting a temporary effect on cell cycle 
regulation or corresponding negative feedback mechanism 
when cells are treated with αIgM (Figure 2B).
Next, we investigated whether BCR activation 
affects the same genes in lymphoma precursor cells in the 
same way as in cultured lymphoma cells. Therefore, the 
expression of cell cycle regulatory genes affected by αIgM 
treatment in BL2 cells was analysed in human tonsillar 
CD10+ B cells. Data were taken from a global gene 
expression analysis of CD10+ B cells from nine different 
donors (Table III, Supplementary Table S3). Although 
there are single BCR.1 genes that were not suppressed by 
BCR activation in human tonsillar CD10+ B cells, most 
of the analysed genes are suppressed by BCR stimulation 
as observed for BL2 cells. Thus, based on the common 
suppression of BCR.1 genes in cultured B lymphoma 
cells and in CD10+ human B cells, we conclude that this 
transcriptional regulation represents a common functional 
pathway of activated BCR signaling.
In addition, cell lines derived from DLBCL, U2932, 
HT, SUDHL5 and SUDHL6, were analysed for the 
presence of the BCR.1 index and whether it is affected 
by αIgM treatment. The BCR.1 index was detectable 
in HT and U2932 cells (Supplementary Figure S1A). 
Stimulation of DLBCL cell lines with αIgM led to a strong 
downregulation of BCR.1 genes (index increase) with 
the exception of SUDHL6 (Supplementary Figure S1B), 
indicating that down-regulation of BCR.1 index genes is 
also observed in DLBCL.
A prolongation of G2/M transition in αIgM 
stimulated human B cells
Since many genes of the BCR.1 gene cluster are 
involved in the regulation of mitotic processes, we 
next studied if BCR signaling had an inhibitory effect 
on mitosis. Cell cycle progression was monitored 
Table I: Identification of different clusters of genes displaying a coherent expression across patient profiles affected 
by multiple in vitro interventions using guided clustering
intervention Index name Number of genes coherently 
expressed in DLBCL
Gene expression changes in 
BL2 cells
αIgM
BCR.1 288 suppressed
BCR.2 286 activated
CD40L
CD40.1 288 suppressed
CD40.2 71 activated
BAFF
BAFF.1 255 suppressed
BAFF.2 122 activated
IL21
IL21.1 148 suppressed
IL21.2 13 activated
LPS
LPS.1 34 suppressed
LPS.2 37 activated
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Table II: Genes of coherent expression across patient profiles reflecting the activity of a branch of B cell receptor 
signaling 
1 XPO1 50 RFC3 99 CLINT1 148 SFRS4 197 BBS10 246 MRPL49
2 PMS1 51 ECT2 100 DLAT 149 HSPH1 198 ZNF638 247 CSE1L
3 RNASEN 52 DSCC1 101 RIOK2 150 FOSL1 199 SRBD1 248 PLA2G12A
4 LBR 53 C12orf48 102 CKAP2 151 KIAA0406 200 GTF2E1 249 ELP4
5 CETN3 54 WRAP53 103 NARS2 152 DSN1 201 MEN1 250 UBTF
6 DCK 55 PARP2 104 CEP76 153 PRPF4B 202 LSM2 251 GTF3C1
7 GPN3 56 TRIP13 105 CACYBP 154 C13orf34 203 SRPK1 252 BCOR
8 SLBP 57 KIF11 106 TMEM97 155 BAG2 204 TTRAP 253 C5orf22
9 RHOT1 58 AASDHPPT 107 POLE2 156 ZNHIT3 205 ZNF184 254 TTC33
10 CAND1 59 FARSA 108 USP13 157 PDHB 206 MICB 255 PSME4
11 RACGAP1 60 CTCF 109 RAD1 158 CCDC56 207 TUBD1 256 PPM1B
12 KIF20A 61 RNASEH2A 110 GCDH 159 CUTC 208 NFYB 257 PIAS4
13 AURKA 62 NEIL3 111 CPOX 160 C14orf104 209 KIF18B 258 WBP4
14 HMMR 63 STIL 112 CLPX 161 COX11 210 PRDM10 259 ACAP2
15 NDC80 64 TARDBP 113 MORC2 162 CDK8 211 HMGN4 260 GRSF1
16 CDC20 65 ARMC1 114 RFC5 163 C8orf41 212 RAD54B 261 GADD45GIP1
17 CENPA 66 MRPL35 115 RAD51C 164 AURKAIP1 213 DTWD1 262 MSH2
18 PLK1 67 WDR67 116 RCN2 165 IMP3 214 BRD8 263 DTYMK
19 NEK2 68 NUP37 117 PIGF 166 MINA 215 TRMT61B 264 FRAT2
20 CCNA2 69 MRPL12 118 ACTR6 167 PUM2 216 RNF34 265 STAMBP
21 KIF18A 70 RAD54L 119 CDC73 168 DHX29 217 CDC27 266 C17orf75
22 RMI1 71 C16orf53 120 MDM1 169 COASY 218 EXOC1 267 FANCL
23 PBK 72 ALG6 121 KIAA0528 170 THAP7 219 SACM1L 268 SFRS2B
24 PRC1 73 TROAP 122 PARG 171 MRPS34 220 VPS33B 269 HMBS
25 BUB1B 74 CDC7 123 THAP11 172 CCDC51 221 SUCLA2 270 PAAF1
26 PLK4 75 RFC4 124 C12orf52 173 MRPL17 222 MRS2 271 NAA40
27 CDCA8 76 UNG 125 PTCD3 174 COIL 223 C6orf211 272 NDUFS3
28 NCAPH 77 PPAT 126 CASP6 175 ATMIN 224 HMGB3 273 DUT
29 TMEM48 78 FASTKD1 127 CTR9 176 SMARCAL1 225 GEMIN6 274 STRA13
30 OIP5 79 KIF15 128 MRPL46 177 COQ9 226 MRPS16 275 HADH
31 CEP55 80 ANP32A 129 GPSM2 178 COBRA1 227 MCM10 276 SEPHS1
32 KIF14 81 SRRD 130 NDUFC1 179 MED20 228 AP1AR 277 ABHD10
33 ESPL1 82 LRRC47 131 UBE2G1 180 CCDC99 229 C4orf27 278 SLC4A1AP
34 POLA2 83 PREB 132 PRPSAP1 181 SIP1 230 FASTKD3 279 STRADA
35 FEN1 84 ZC3H14 133 NCAPD3 182 FANCG 231 CLCN3 280 CBX1
36 BRCA1 85 TTK 134 DPF2 183 MCM2 232 PRMT5 281 MRPS27
37 TUBG1 86 EFTUD1 135 HEATR3 184 CRIPT 233 TDP1 282 WRB
38 MRPL16 87 OSBPL11 136 SHCBP1 185 GAPVD1 234 LARS2 283 DERA
(Continued )
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Table III: Genes involved in different aspects of cell cycle regulation as described by guided clustering for BCR.1 
Gene symbol Name Function in cell cycle and related 
processes
Fold 
change 
(log2FC)
Fold 
change 
(log2FC)
BL2 CD10+ 
tonsilar B 
cells
1 ASPM asp (abnormal spindle) homolog role in mitotic spindle regulation and 
coordination of mitotic processes
-0,51 -0,45
2 ATMIN ATM interactor ATM/ATR-substrate CHEK2-
interacting zinc finger protein; Plays 
a crucial role in cell survival and 
RAD51 foci formation in response to 
methylating DNA damage. Involved in 
regulating the activity of ATM in the 
absence of DNA damage
-0,39 n.a.
3 AURKA Aurora-kinase A Mitotic serine/threonine kinases that 
contributes to the regulation of mitosis
-0,68 -1,03
4 BARD1 BRCA1 associated RING 
domain 1
Constitutes together with BRCA1 an 
Ubiquitin E3 ligase
-0,68 -0,53
5 BCOR BCL6 corepressor Transcriptional corepressor -0,69 -0,43
6 BIRC5/Survivin baculoviral IAP repeat 
containing 5
Component of the chromosomal 
passenger complex (CPC), a complex 
that acts as a key regulator of mitosis
-0,45 -0,44
7 BRCA1 breast and ovarian cancer 
susceptibility protein 1
Constitutes together with BARD1 an 
ubiquitin E3 ligase. Involved in DNA 
repair and in the regulation of mitosis.
-0,44 -0,32
8 BUB1B/
MAD3L/BUBR1
budding uninhibited by 
benzimidazoles 1 homolog beta
Essential component of the mitotic 
spindle assembly checkpoint
-0,37 -0,608
9 C12orf52 RBP-J interacting and tubulin 
associated
Tubulin-binding protein that acts as a 
negative regulator of Notch signaling 
pathway
-0,83 n.a.
(Continued )
39 TACC3 88 MYCBP 137 C4orf41 186 CNP 235 BARD1 284 SAR1B
40 SAC3D1 89 DYNLL1 138 SKP2 187 RAB11A 236 MSH3 285 MAP3K4
41 ASPM 90 NIF3L1 139 MTX2 188 MRPS31 237 MPHOSPH6 286 KIAA1279
42 WDHD1 91 MRFAP1L1 140 MUDENG 189 MRPL34 238 MTIF2 287 PPCS
43 BIRC5 92 NARG2 141 C15orf44 190 PHB 239 ATR 288 C5orf15
44 CCNB1 93 SPAST 142 GINS1 191 POP4 240 PPP2R5E
45 ASF1B 94 ZW10 143 ZWILCH 192 AGGF1 241 PSMC6
46 ORC1L 95 ELF2 144 MRPL18 193 KIF22 242 ZNF107
47 KIF2C 96 ADH5 145 PEX14 194 POP7 243 EIF2B4
48 CDCA3 97 ORC4L 146 TOMM70A 195 DDX23 244 C9orf40
49 FOXM1 98 ORC2L 147 TSN ZBED5 245 RTF1
Shown are the genes of the newly identified transcriptional module called BCR.1. For all transcriptional modules please 
refer to TABLE E1.
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Gene symbol Name Function in cell cycle and related 
processes
Fold 
change 
(log2FC)
Fold 
change 
(log2FC)
BL2 CD10+ 
tonsilar B 
cells
10 C13orf34/bora aurora kinase A activator Required for the activation of AURKA 
at the onset of mitosis
-0,42 -0,417
11 CCNA2 Cyclin A2 binds and activates CDK1 or CDK2 
kinases, and thus promotes both cell 
cycle G1/S and G2/M transitions
-0,42 -0,57
12 CCNB1 Cyclin B1 Binds and activates CDK1, Eessential 
for the control of the cell cycle at the 
G2/M (mitosis) transition
-0,67 -0,67
13 CDC20 cell division cycle 20 homolog In metaphase the MAD2L1-CDC20-
APC/C ternary complex is inactive 
and in anaphase the CDC20-APC/C 
binary complex is active in degrading 
substrates
-0,57 -0,87
14 CDC27 Anaphase-promoting complex 
subunit 3
Subunit of the APC/C, cell cycle-
regulated E3 ubiquitin ligase that 
controls progression through mitosis 
and the G1 phase
-0,27 -0,52
15 CDC7 cell division cycle 7 homolog G1/S phase transition -0,35 -0,70
16 CDCA3 Trigger of mitotic entry protein 1 F-box-like protein which is required for 
entry into mitosis. Acts by participating 
in E3 ligase complexes
-0,54 -0,66
17 CENPA centromere protein A Histone-like protein, Required 
for recruitment and assembly 
of kinetochore proteins, mitotic 
progression and chromosome 
segregation
-0,52 -1,05
18 CETN3 centrin located at the centrosome of interphase 
and mitotic cells, where it plays 
a fundamental role in centrosome 
duplication
-0,99 -0,67
19 COBRA1 cofactor of BRCA1 Essential component of the NELF 
complex, a complex that negatively 
regulates the elongation of 
transcriptionby RNA polymerase II
-0,37 n.a.
COIL coilin During mitosis, CBS disassemble, 
coinciding with a mitotic-specific 
phosphorylation of p80coilin
n.a -0,23
20 CSE1L CSE1 chromosome segregation 
1-like
may play a role both in apoptosis and in 
cell proliferation
-0,34 -0,37
21 DSCC1 Defective in sister chromatid 
cohesion protein 1
couple DNA replication to sister 
chromatid cohesion through regulation 
of the acetylation of the cohesin subunit 
SMC3
-0,55 -0,37
(Continued )
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Gene symbol Name Function in cell cycle and related 
processes
Fold 
change 
(log2FC)
Fold 
change 
(log2FC)
BL2 CD10+ 
tonsilar B 
cells
22 DSN1 MIND kinetochore complex 
component, homolog (S. 
cerevisiae)
MIND kinetochore complex component -0,69 -0,41
23 ECT2/ARH-
GEF31
Epithelial cell-transforming 
sequence 2 oncogene
Required for signal transduction 
pathways involved in the regulation of 
cytokinesis
-0,31 -0,70
24 ESPL1 extra spindle pole bodies 
homolog 1
Caspase-like protease, which plays 
a central role in the chromosome 
segregation by cleaving the SCC1/
RAD21 subunit of the cohesin complex 
at the onset of anaphase
-0,35 -0,42
25 FANCG Fanconi anemia, 
complementation group L
maintenance of normal chromosome 
stability
-0,51 -0,42
26 FANCL Fanconi anemia, 
complementation group L
mediates monoubiquitination of 
FANCD2, a key step in the DNA 
damage pathway
-0,72 -0,65
27 FOSL1/FRA1 FOS-like antigen 1 regulators of cell proliferation -0,28 +0,22
28 FOXM1 forkhead box M1 Transcriptional factor regulating the 
expression of cell cycle genes essential 
for DNA replication and mitosis
n.a -0,33
29 FRAT2 frequently rearranged in 
advanced T-cell lymphomas 2
Positively regulates the Wnt signaling 
pathway by stabilizing beta-catenin 
through the association with GSK-3
-0,96 n.a.
30 GADD45GIP1 growth arrest and DNA-damage-
inducible, gamma interacting protein 1
-1,56 n.a.
31 HMMR/
RHAMM
hyaluronan-mediated motility 
receptor
Receptor protein and associated with 
mitotic spindles
-0,86 -0,99
32 KIAA0406 TELO2 interacting protein 1 Regulator of the DNA damage response -0,32 n.a.
33 KIF11/KSP/Eg5 kinesin family member 11 Motor protein required for establishing 
a bipolar spindle.
n.a -0,71
34 KIF14 kinesin family member 14 Plays an essential role in cytokinesis -0,45 -0,75
KIF15 HKLP2, kinesin family member 
15
Plus-end directed kinesin-like motor 
enzyme involved in mitotic spindle 
assembly
-0,67 -0,51
35 KIF18A kinesin family member 18A Microtubule-depolymerizing kinesin 
which plays a role in chromosome 
congression.
-0,56 -0,38
36 KIF18B Kinesin family member 18B Microtubule-depolymerizing kinesin n.a -0,49
37 KIF20A Rab6-interacting kinesin-like 
protein
Mitotic kinesin required for 
chromosome passenger complex 
(CPC)-mediated cytokinesis
-1,65 -1,26
(Continued )
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Gene symbol Name Function in cell cycle and related 
processes
Fold 
change 
(log2FC)
Fold 
change 
(log2FC)
BL2 CD10+ 
tonsilar B 
cells
38 KIF22 Kinesin family member 22 movements of chromosomes during 
mitosis
-0,36 -0,27
39 KIF2C/MCAK Mitotic centromere-associated 
kinesin
Microtubule depolymerase, Regulates 
the turnover of microtubules at 
kinetochores
n.a -0,36
40 MINA MYC induced nuclear antigen Involved in cellular proliferation -0,64 n.a.
41 MYCBP MYC-binding protein May control the transcriptional activity 
of MYC
-0,33 -0,97
42 NEK2 NIMA (never in mitosis gene a)-
related kinase 2
control of centrosome separation and 
bipolar spindle formation in mitotic 
cells
-0,64 -0,58
43 NCAPD3 non-SMC condensin II complex, 
subunit D3
Regulatory subunit of the condensin-2 
complex, a complex which establishes 
mitotic chromosome architecture and 
is involved in physical rigidity of the 
chromatid axis
n.a -0,24
44 NCAPH non-SMC condensin I complex, 
subunit H
Regulatory subunit of the condensin 
complex, a complex required for 
conversion of interphase chromatin into 
mitotic-like condense chromosomes
n.a -0,43
45 NDC80 NDC80 homolog kinetochore complex component n.a -0,97
46 OIP5 Opa interacting protein 5 Required for recruitment of CENPA to 
centromeres and normal chromosome 
segregation during mitosis
-0,61 -0,74
47 PARP2 poly (ADP-ribose) polymerase 2 Involved in the base excision repair 
(BER) pathway,
-0,33 -0,49
48 PBK/TOPK PDZ-binding kinase Phosphorylates MAP kinase p38, active 
only in mitosis. May also play a role in 
the activation of lymphoid cells. When 
phosphorylated, forms a complex with 
TP53, leading to TP53 destabilization 
and attenuation of G2/M checkpoint 
during doxorubicin-induced DNA 
damage
-0,66 -0,51
49 PLK1 Polo-like kinase 1 critical regulatorsof cell cycle 
progression, mitosis, cytokinesis, and 
the DNA damage response
-0,78 -0,29
50 PLK4/STK18 Polo-like kinase 4 able to induce centrosome amplification 
through the simultaneous generation 
of multiple procentrioles adjoining 
each parental centriole during S phase. 
Phosphorylates CDC25C and CHEK2
-0,27 -0,31
(Continued )
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Gene symbol Name Function in cell cycle and related 
processes
Fold 
change 
(log2FC)
Fold 
change 
(log2FC)
BL2 CD10+ 
tonsilar B 
cells
51 PMS1 DNA mismatch repair protein involved in the repair of mismatches in 
DNA
-1,24 n.a.
52 PRC1 protein regulator of cytokinesis 1 Required for KIF14 localization to the 
central spindle and midbody.
-0,57 -0,63
53 PRDM10 PR-domain family member 7 transcriptional regulation, involved 
in B cell differentiation and tumour 
suppression
-1,32 n.a.
54 PUM2 pumilio homolog 2 Sequence-specific RNA-binding 
protein, support proliferation andself-
renewal of stem cells
-0,32 n.a.
55 RAD1 Rad1-like DNA damage 
checkpoint protein
cell cycle checkpoint protein -0,28 n.a.
56 FANCO/
RAD51C
RAD51 homolog C early function in DNA repair in 
facilitating phosphorylation of the 
checkpoint kinase CHEK2 and thereby 
transduction of the damage signal, 
leading to cell cycle arrest and HR 
activation
-0,32 n.a.
57 RAD54B DNA repair and recombination 
protein RAD54B
Involved in DNA repair and mitotic 
recombination
-0,96 -0,45
58 RAD54L DNA repair and recombination 
protein RAD54-like
Involved in DNA repair and mitotic 
recombination
-0,49 -0,23
59 RFC3 replication factor C 
(activator 1) 3
elongation of primed DNA templates 
by DNA polymerase delta and epsilon 
requires the action of the accessory 
proteins proliferating cell nuclear 
antigen (PCNA) and activator 1
-0,53 n.a.
60 RMI1 RecQ mediated genome 
instability 1
important role in the processing 
ofhomologous recombination 
intermediates to limit DNA crossover 
formation in cells
-0,54 n.a.
61 RNASEN drosha, ribonuclease type III is involved in the initial step 
ofmicroRNA (miRNA) biogenesis
-0,71 n.a.
62 SAC3D1 SAC3 domain containing 1 Involved in centrosome duplication and 
mitotic progression
-1,05 -1,01
63 SKP2 S-phase kinase-associated 
protein 2 - E3 ubiquitin 
protein ligase
subunit of the SCF ubiquitin ligase -0,95
64 SPAST spastin completion of the abscission stage of 
cytokinesis
-0,83 -0,53
(Continued )
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Gene symbol Name Function in cell cycle and related 
processes
Fold 
change 
(log2FC)
Fold 
change 
(log2FC)
BL2 CD10+ 
tonsilar B 
cells
65 STIL SCL/TAL1 interrupting locus its long-term silencing affects cell 
survival and cell cycle distribution 
as well as decreases CDK1 
activity correlated with reduced 
phosphorylation of CDK1
n.a -0,43
66 STRADA STE20-related kinase adaptor 
alpha
necessary for STK11-induced G1 cell 
cycle arrest
-0,48 -0,35
67 STRA13/
FANCM/
CENP-X
Fanconi anemia-associated 
polypeptide
involved in DNA damage repair and 
genome maintenance
-0,38 -0,275
68 TACC3 transforming, acidic coiled-coil 
containing protein 3
microtubule-associated adaptor protein -0,41 -0,51
69 TTK/MPS1 Phosphotyrosine picked 
threonine-protein kinase
Essential for chromosome alignment 
by enhancing AURKB activity (via 
direct CDCA8 phosphorylation) at 
the centromere, and for the mitotic 
checkpoint
-0,37 -0,45
70 TUBG1 Tubulin G1 major constituent of microtubules, -0,61 n.a.
71 UBE2G1 ubiquitin-conjugating enzyme 
E2G 1
member of theE2 ubiquitin-conjugating 
enzyme family and catalyzes the 
covalent attachment of ubiquitin to 
other proteins
-0,77 -0,55
72 ZW10 kinetochore associated, homolog Essential component of the mitotic 
spindle assembly checkpoint
-0,305 n.a.
Data are extracted from U133 plus 2.0 microarray analysis. Differentially expressed genes were identified using linear 
models as implemented in the Bioconductor package LIMMA [32, 68]. Shown are the data for αIgM treated BL2 cells 
(triplicate) and from nine individual CD10+ tonsillar B cells stimulated in vitro. n.a. – not affected. BL2 data are part of 
the heatmap in Figure 1A and TABLE II, whereas gene expression changes of CD10+ tonsillar B cells are extracted from 
Supplementary Table S3.
using flow cytometry to define the percentage of the 
diploid and tetraploid sets of chromosomes [41, 42]. In 
asynchronously growing BL2 and Ramos cells, αIgM 
treatment led to a delay in G2/M as revealed by an 
increase in the percentage of cells with a 4N DNA content 
(Figure 3A). To obtain a better functional insight into the 
effects of BCR activation on cell cycle regulation, Ramos 
cells were synchronized at the G1/S transition. After 
release from thymidine block, cells where left untreated 
or stimulated by αIgM. Cell cycle progression was 
monitored using flow cytometry at defined time points as 
shown in Figure 3B. Within 4hrs both untreated or αIgM 
treated cells entered the G2 phase of the cell cycle. While 
untreated cells progressed through mitosis within 5-6hrs, 
αIgM treated cells were delayed by approximately 
1-2hrs. Figure 3C shows the percentage of the 2N and 
4N DNA content. Analyses of the phosphorylation of 
Histone 3 as a mitotic marker (pHistoneH3) showed 
that pHistone-H3 peaks after 5hrs in control cells in 
contrast to αIgM treated cells, which peaks at 6.5hrs 
(Figure 3D). After 8hrs no phosphorylation remains. 
Interestingly, the phosphorylation of this mitotic marker 
is generally decreased in cells activated via the BCR. 
To quantify the effect, the mitotic index of thymidine 
synchronized BL cells was analysed by measuring 
the percentage of pMPM3 positive cells. In αIgM 
treated cells the number of pMPM3 positive cells was 
lower compared to untreated cells (Figure 3E) further 
supporting the view that the activation of the BCR 
signaling pathway leads to a delay in G2 and/or lag 
in progression through the mitotic phase of the cell 
cycle. This is in agreement with the observed reduced 
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expression of cell cycle regulators from the BCR.1 gene 
cluster. Immunoblot analysis for Aurora-A, Aurora-B, 
Tpx2 or Mad2 and the phosphorylated forms of Aurora-A 
and -B revealed corresponding changes in protein levels 
and phosphorylation patterns (Figure 3F). In line with a 
delay in mitotic progression, activation (phosphorylation) 
of the key mitotic kinases, Aurora-A and Aurora-B, 
was prolonged in BCR-activated BL cells (Figure 3F). 
Untreated cells enter M phase 4-6 hrs after release of the 
cell cycle block. After 8 hrs most of the cells have left 
mitosis as shown by a peak of TPX2 levels at 6hrs and the 
sharp decline of TPX2 after 8hrs (Figure 3F). However, 
cells that have been activated via BCR enter mitosis at 
the latest after 8hrs and need 10hrs to complete mitosis. 
The prolongation of the G2 phase as well as the observed 
delay of entry into mitosis could be an indication that 
BCR activation suppresses mitotic processes.
Therefore, defects in mitosis were investigated 
and quantified. Synchronized BL cells were released 
from cell cycle block as described above in the presence 
or absence of αIgM. 2hrs before harvesting, cells were 
treated with the proteasome inhibitor MG132 to arrest 
cells in metaphase. In Ramos cells treated with MG132 
alone, metaphase chromosomes were found to be properly 
aligned at the equatorial plane. Abnormal metaphases were 
increased in αIgM treated cells (Figure 3H), suggesting 
Figure 2: Expression of genes from the BCR.1 gene module is deliberately suppressed in lymphoma cells. A. Expression 
of the genes for PLK1, AURKA, NEK2, BUB1B, CDC20, MPS1, BIRC5, HMMR, TACC3 and KIF14A in response to αIgM treatment was 
analysed in BL2 and Ramos cells using qRT-PCR. One representative experiment out of three is shown. All samples were analysed in 
triplicate. Expression of the genes is shown as 2-ΔΔCT relative to abl housekeeper expression and compared to unstimulated control. B. Time 
dependent suppression of genes as in Figure 2A by αIgM treatment of BL2 cells. Data are taken from Human ST1.0 microarray analysis. 
Differentially expressed genes were identified using linear models as implemented in the Bioconductor package LIMMA [68].
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that BCR signaling causes chromosome missegregation 
and subsequent accumulation of karyotype abberations.
To test this, a chronic activation of BCR was 
mimicked by culturing Ramos cells over 3 weeks with 
daily addition of αIgM F(ab)2 fragments. In Figure 4 A/B 
cell viability and cell doubling data are presented from 
these experiments. A decrease of cell viability within the 
first 10 days was accompanied by a very low cell doubling. 
This fits well with earlier observations of increased cell 
death in BL cells after in vitro BCR activation monitored 
as cell cycle arrest within G1 [43]. However, after 
two weeks both cell proliferation and viability were 
increased. Analysis of the karyotypes of chronically 
treated Ramos cells revealed additional chromosomal 
aberrations including translocations (t(15;21)(q14?;q22)) 
as well as additions (add(16)(q24)) (Figure 4). These 
structural abnormalities were not observed in untreated 
BL cells. One explanation for the induction of additional 
chromosomal abberations could be that chronic exposure 
of B cells to antigens and thus BCR activation can lead to 
subsequent cell cycle changes predisposing cells for the 
acquisition of subsequent chromosomal aberrations.
Gene suppression is negatively associated with 
c-Myc activity after B cell receptor activation
It was shown recently that in BL cell lines αIgM 
treatment is associated with a PI3K dependent decrease 
in MYC expression [32]. Therefore, the involvement of 
c-Myc in BCR.1 gene regulation, particularly on cell cycle 
regulators and on cell cycle deregulation induced by αIgM 
was evaluated.
First, a patient-based comparison between the 
BCR.1 index with our recently established Myc-index 
Figure 3: BCR activation is associated with a prolongation of the G2 phase, a deceleration of M phase entrance and 
metaphase defects. A. Percent of BL2 and Ramos cells in different cell cycle phases with and without αIgM stimulation. Asynchronous 
growing BL cell line Ramos cells were stimulated by αIgM and cell cycle changes were detected using flow cytometry according to 
Nicoletti 6h after stimulation. B. Monitoring of the passage of synchronized Ramos cells through the cell cycle. Double thymidine block 
synchronized cells were released from cell cycle block and simultaneously stimulated using αIgM or left untreated. C. Percentage of cells 
within the different cell cycle phases as monitored by flow cytometry as in B. D. Changes in Histone 3 phosphorylation of synchronized 
Ramos cells after release from cell cycle block and simultaneously stimulated using αIgM or left untreated as monitored by immunoblot. 
E. Determination of the percentage of mitotic cells measured by phosphorylation of MPM2 (pMPM2) by flow cytometrical analyses 
of fixed cells 12h after stimulation. F. Thymidine synchronized Ramos cells were released from cell cycle block and treated as in B. 
Phosphorylation of AUROKA and AUROKB and their expression was monitored in unstimulated and αIgM stimulated cells in comparison 
to MAD2 and TPX2 as described recently [42]. Changes in Aurora kinase phosphorylation and TPX protein levels as measured by 
ImageJ quantification analysis shown within the Supplementary Figure S2. G. Detection of defective metaphases in αIgM stimulated cells 
quantified by microscopy. Thymidine synchronized Ramos cells were released from cell cycle block and treated as described in B. Two 
hours before harvesting cells were treated with 10µM MG132. Cells were stained with DAPI. H. The percentage of defect metaphases was 
calculated as monitored by microscopy exemplified in G.
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was performed [20]. The correlation coefficients of these 
two indices were calculated in gene expression profiles of 
219 B-NHL including molecularly defined BLs (mBLs), 
non-mBLs and intermediate lymphoma (molecularly 
unclassified B-NHLs) [30]. The correlation coefficient 
is -0.76 (Figure 5A). Thus, the BCR.1 index inversely 
correlates with the c-Myc index. Figure 5A shows both 
index values per sample. Therefore, mBL cases are 
characterized by a high c-Myc but a low BCR.1 index, 
whereas non-mBLs and intermediate lymphoma are more 
heterogeneous with a lower c-Myc and higher BCR.1 
index. Lymphomas with a high BCR.1 signal can be 
characterized by a very low c-Myc activity and therefore 
can be grouped as BCR.1high/Myclow NHL. The majority of 
non-mBLs and intermediate lymphoma are characterized 
by corresponding higher BCR.1 but lower c-Myc activity 
relative to mBLs. Comparison of the BCR.1 index with 
BCL6 regulated genes was performed in patient samples 
(Supplementary Figure S3) [28, 44]. Although a good 
separation of mBLs from intermediate and non-mBLs was 
observed, the index correlation (-0.1) was not as strong 
as for c-Myc. Therefore, the c-Myc protein levels were 
scored on tissue microarrays (TMA) of 99 lymphoma 
cases taken from the MMML-cohort described above 
[30]. In parallel, the BCR.1 index for these cases based on 
their gene expression profiles was calculated. This analysis 
revealed that cases with higher numbers of c-Myc positive 
lymphoma cells were significantly more likely to express 
BCR.1 genes (low BCR.1 index) (p=0.0012) (Figure 5B). 
This finding underscores the negative correlation of 
c-Myc and BCR.1 indices and supports the definition of a 
BCR.1high Myclow NHL subgroup (mainly DLBCL).
To assess whether the cell cycle delay after BCR 
activation might be the result of the BCR induced 
inhibition of c-Myc, we investigated whether the inhibition 
of c-Myc alone can induce G2-phase prolongation of 
thymidine synchronized Ramos cells. Double thymidine 
block synchronized Ramos cells were released from cell 
cycle block and treated with the chemical Myc inhibitor 
10058-F4, αIgM, or both. Within 4hrs all cells entered 
the G2 phase of the cell cycle. While untreated cells 
entered the G1 phase of the cell cycle within 5-6hrs αIgM, 
10058-F4 and αIgM/10058-F4 treated cells were delayed 
(Figure 5C). The prolonged G2 phase in 10058-F4 treated 
cells was comparable to the effect of αIgM treatment alone 
and thus supports the inverse correlation of BCR.1 and 
the Myc index shown in Figure 5A/B. The strongest delay 
was observed by the combination of BCR activation and 
c-Myc inhibition. Therefore, αIgM treatment together 
with 10058-F4 shows an additive effect on G2 phase 
prolongation. This suggests that the BCR effect on the cell 
cycle regulation is not solely the result of inhibiting MYC 
expression. In Figure 5D the percentage of the diploid and 
tetraploid sets of chromosomes is shown.
The role of aberrant c-Myc activity on cell cycle 
and BCR.1 gene regulation was analysed by qRT-PCR 
Figure 4: Continiously αIgM treated B cells are characterized by additional chromosomal aberrations. A. Ramos cells 
were treated with αIgM or left untreated for at least 21 days adding αIgM every 24hrs after adjusting cell numbers according to untreated 
cells. Data are presented as proliferation rate (see additional details within the supplementary Material and Methods section). B. Cell 
viability of Ramos cells was measured by the number of propidium-iodide positive Ramos cells using FACS. C. Karyotype of Ramos 
cells in the absence of BCR activation. Karyotype of Ramos after chronic αIgM stimulation for 21 D. and 28 days E. respectively. 
F. M-FISH of Ramos cells in the absence of BCR activation. M-FISH of Ramos cells after chronic αIgM stimulation for 21 G. and 28 
days H. respectively. Shown are additional chromosome aberrations of add(16)(q24) after 21d (D/G) and of t(15;21)(q14?;q22) after 
28days (E/H) αIgM treatment respectively.
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as shown for BUB1B and other BCR.1 genes in BL2 
and Ramos cells treated with 10058-F4, αIgM or both 
(Figure 5E, Supplementary Figure S4). The expression 
of some BCR.1 genes is dependent on aberrant c-Myc 
activity, but BCR activation and c-Myc inhibition act in 
an additive manner.
In addition we tested by chromatin-
immunoprecipitation (ChIP) whether c-Myc binding 
to a known E-box containing region in the first intron 
of the BUB1B gene is altered upon BCR activation 
[45, 46]. The gene locus of the BUB1B gene was 
enriched by ChIP of c-Myc in unstimulated cells 
(Figure 5F). Importantly, following BCR activation 
this enrichment was abolished. As positive control a 
ChIP of acetylated histone H3 was used as a marker 
for active transcription. Therefore, a critical cell cycle 
regulator is suppressed in response to suppression of 
MYC gene expression by αIgM. However, the observed 
additive effect of BCR activation together with 10058-
F4 treatment also indicates that additional pathways are 
involved through BCR activation which could mediate 
the suppression of the BCR.1 genes.
Figure 5: c-Myc is involved in the regulation of cell cycle regulators from the BCR.1 gene cluster. A. The BCR.1 index 
is inversely correlated with the c-Myc index in distinct groups of lymphoma patients and discriminates Burkitt lymphoma from diffuse 
large B cell lymphoma. The parallel activity was estimated plotting the BCR.1 and c-Myc indices against each other and calculating the 
respective correlation coefficient. The correlation coefficients of the BCR.1 index and the c-Myc index were calculated in gene expression 
profiles of 219 aggressive NHL [30]. The NHL cases were assigned to the following molecular categories: mBL (red), non-mBL (green) 
and intermediate lymphoma (yellow) based on their gene expression profiles [30]. B. The BCR.1 index is inversely correlated to the 
number of c-Myc positive cells in NHL. c-Myc protein levels were determined using immunohistochemical staining of tissue-microarrays. 
The scoring was performed as follows: low expression (0-25% positive cells) and high expression (25-100 % positive cells). C. B cell 
receptor activation and c-Myc-inhibition delays the G2/M cell cycle phase transition in an additive way as monitored by the passage 
of synchronized Ramos cells through the cell cycle. Double thymidine block synchronized Ramos cells were analysed as described in 
Figure 3. D. Percentage of cells within the different cell cycle phases monitored by flow cytometry as in C. E. qRT-PCR analysis of BUB1B 
gene expression in BL2 (black bars) or Ramos cells (grey bars). BL2 and Ramos cells were pretreated for 3h with 60µM 10058-F4 c-Myc 
inhibitor or solvent (DMSO). Cells were stimulated for an additional 3h with αIgM F(ab)2 fragment (12µg/ml). qRT-PCR analyses were 
performed using SYBR green. Fold changes were calculated using the ΔΔCt method. One representative experiment of three replicates is 
shown. Additional BCR.1 genes are shown in the extended view figure E1. F. c-Myc binds to the BUB1B gene. A fragment was amplified 
that encompasses the previously described E-box in intron 1 of the BUB1B gene [45]. ChIP was performed using antibodies directed against 
IgG as a negative control (lanes 3,4), against c-Myc (lanes 5,6) and against acetylated histone H3 as positive control (marker for active 
transcription) (lanes 7,8). c-Myc binds to the BUB1B gene (lane 5) but this binding is lost as a result of B cell receptor activation (lane 6).
The lower electropherogram shows a shorter exposure time to show differences in acetyl Histone H3 binding.
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The BCR.1 gene module characterizes 
individual NHL and is more active within 
GCB-like DLBCL
To further study the functional relevance of the 
BCR.1 gene module in specific subgroups of B-NHL 
and specifically in DLBCL, we compared by the gene 
expression profiles of 389 primary lymphoma samples 
[30, 47]. Figure 6A shows that mBLs (colored in red) 
are characterized by a low or absent BCR.1 index. This 
was also observed for samples characterized by MYC-
aberrations. About 20% of analysed non-mBLs show a 
strong coherently low expression of BCR.1 genes and 
therefore are characterized by a strong corresponding BCR 
signal. This is in good agreement with the observation 
presented in Figure 1B within the „training cohort“ and 
the observed inverse correlation of the BCR.1 and c-Myc 
indices (Figure 5A). A comparison of ABC- and GCB-like 
DLBCLs in this analysis is difficult as mBLs are labelled 
also as GCB-like lymphomas. Therefore, an additional 
analysis was performed (Figure 6B). Comparing 281 non-
mBL DLBCL samples, we observed a significantly higher 
BCR.1 index in GCB-DLBCL (n=159) compared with 
ABC-like DLBCL (n=122) (p=9.35e−06). This supports 
the view that more GCB-like DLCBL are characterized 
by a specific coexpression of BCR.1 genes than are ABC-
like DLBCL.
DISCUSSION
Gene expression based molecular tumour signatures 
have been identified in aggressive NHL. In DLBCL 
specific oncogenic signalling networks have been deduced 
from these signatures. These networks are driven by 
mutations or the microenvironment acting onto the 
lymphoma cells [1, 13, 48, 49]. However, the functional 
effects revealed by these gene expression signatures, are 
poorly understood. A better understanding could improve 
of lymphoma treatments. Therefore, the present study 
aimed to gain further functional insights into oncogenic 
pathways active in aggressive NHL. The guided clustering 
approach was extended to identify transcriptional modules 
that are conserved between patients and in vitro stimulated 
cells but dominantly activated or inhibited by for example 
BCR signaling but not by other well known mediators of 
signalling in B cells. We have provided a comprehensive 
genome-wide resource for the functional exploration 
of molecular and cellular regulation in B cells. Ten new 
transcriptional modules were identified (Figure 1).
Of the ten transcriptional modules we identified, the 
BCR.1 module comprises genes, which are suppressed 
by BCR activation. It was shown that these genes 
are downregulated by BCR activation in a number of 
different cell lines including BL2, Ramos, U2932, HT and 
SUDHL5. We conclude that in patients BCR or related 
pathways are involved in the described way of gene 
coregulation. Furthermore, the BCR.1 module is strong in 
a substantial number of GCB-like DLBCL but not in mBL 
and supports the hypothesis, that in some DLBCL BCR 
signaling is involved in the downregulation of cell cycle 
regulators. Because in ABC-like DLBCLs the BCR.1 
signal is attenuated compared to GCB-like DLBCLs 
(Figure 6B), it would be interesting to determine if the 
coactivity of classical Jak/STAT and NF-κB signaling 
characteristic of ABC-like DLBCL can enhance the BCR.1 
gene expression independent of c-Myc [19, 50].
Figure 6: The BCR.1 index characterizes individual aggressive NHL and discriminates between ABC- and GCB-like 
DLBCL. A. The heatmap is showing the expression of BCR.1 genes (row) in molecular profiles of 389 primary lymphoms samples 
(columns) from distinct patient cohorts [30, 47]. The patient samples are ordered according to rising BCR.1 index from left to right. The 
colour-coded bar on top of the heatmaps represents the affiliation of patients tomBL (red), non-mBL (green) and yellow (intermediate) 
diagnosis. B. Boxplot of the distribution of indices for BCR-repressed genes comparing 281 DLBCL samples based on their relation to 
GCB- and ABC-like DLBCL classification. The difference is highly significant with p=9.35e−06.
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Remarkably, BCR.1 genes are enriched for those 
involved in cell cycle regulation (Figure 2 and Table III). 
The functional outcome of this gene module is a delayed 
entry to and progression of mitosis most probably as a 
result of reduced expression of the identified cell cycle 
regulators (Figure 3). After continuous BCR activation 
some B cells gain additional genetic aberrations (Figure 4) 
as a direct or indirect consequence of the observed changes 
in G2/M cell cycle phase delays. By large-scale follow-up 
analyses of pairs of primary and relapsed aggressive NHL 
it can now be tested which role BCR.1 gene expression 
is playing to affect increases of chromosomal aberrations 
or disease progression. However, this is also an important 
observation as the genes suppressed by BCR activation 
are also found to be downregulated in isolated human 
tonsillar CD10+ B cells. Therefore, it is proposed that these 
genes are functionally relevant in both transformed and in 
reactive B cells.
There is growing evidence of a role for BCR 
signaling in the pathogenesis of different subtypes of NHL. 
In BL a tonic BCR signal is observed whereas in DLBCL 
both tonic and chronic active BCR signaling seem to be 
important [26, 27, 51-53]. As well as supporting B cell 
proliferation, survival or differention, BCR activation can 
also induce G1 cell cycle arrest, apoptosis and increased 
cell death in different B cells [54-59]. Our observations 
suggest that these suicide pathways can be, at least partially, 
attributed to a delay in G2/M with associated mitotic defects 
potentially leading to subsequent chromosomal aberrations. 
Our data also provide a plausible mechanism to explain 
the link between inflammation and the development of 
lymphomagenic mutations; especially in DLBCL with a 
high BCR.1, chronic inflammation and/or chronic antigen 
driven activation of oncogenic pathways with no or low 
c-Myc activity. The inverse correlation of the Myc-index 
and the BCR.1 index suggests that in lymphomas with a 
high MYC expression corresponding BCR.1 genes are 
highly expressed (low BCR.1 index, high gene expression) 
and thus most likely indicates an absence of a strong antigen 
stimulation.
The newly identified oncogenic network present in a 
substantial number of GCB-like DLBCL will likely define 
more rational treatment targets in this heterogeneous 
disease. Whether this has implications for stratifying 
NHL patients for molecular-based prognostication and 
for targeted therapy has to be investigated in new clinical 
trials using R-CHOP and/or currently introduced targeted 
drugs for Btk, PI3K and NF-kB pathways or BET-domain 
containing protein inhibitors [25, 48, 51, 60].
MATERIALS AND METHODS
Cell culture
BL2, Ramos, SUDHL5, SUDHL6, U2932 and HT 
(all obtained from the DSMZ Braunschweig, Germany) 
cell cultivation as well as purification and sorting of 
primary human tonsillar B cells was performed as 
previously described [20, 61] [32]. A detailed protocol 
can be found in the “Extended View Methods Section”. 
For stimulation studies, cells were cultured as described 
previously [32]. Cells chronically activated by αIgM were 
grown for up to 28 days and αIgM was added every 24hrs. 
Cells were harvested using corresponding inhibitors of 
phosphatases and proteases and RNA isolated using 
the RNeasy Plus Mini Kit (Qiagen). Cell doubling and 
viability was determined by counting cells in the presence 
of trypan blue.
Synchronisation of BL cells was performed using 
thymidine treatment as recently described [62]. Cell 
cycle analysis was performed on the basis of analysing 
the DNA content in the nuclei of the cells by propidium 
iodide staining followed by flow cytometry. For a 
detailed description see the “Expanded View Methods 
Section”.
Gene expression analysis
qRT-PCR was performed using SYBR green. 
ΔCt values were normalised to ß2m and abl expression 
and ΔΔCt values calculated. Oligonucleotides used 
are summarized in Supplementary Table S4. For whole 
genome micorarrays Human Genome U133A 2.0 plus 
Arrays (Affymetrix) or Human ST1.0 Arrays (Affymetrix) 
as indicated was performed according to manufacturer’s 
recommendations by the TAL (UMG, Germany) For 
further details of gene expression analyses see the 
“Expanded View Methods Section”.
Cytogenetic analysis
Metaphases were analysed using chromosome 
banding analysis and 24-color FISH. Chromosome 
preparation was performed using standard cytogenetic 
protocols and modified chromosome banding technology 
(GAG// Giemsa bands of acetic Saline Giemsa). M-FISH 
(24 color FISH) was done according to the manufacturer’s 
protocol (MetaSystems). Karyotypes were classified 
according to the International System for Human 
Cytogenetic Nomenclature (ISCN) [63].
Chromatin immunoprecipitation
BL2 cells were stimulated with 1.3µg/ml αIgM 
F(ab)2 fragments for 3hrs or left untreated as control. 
Cells were sedimented and resuspended in PBS containing 
1.42% formaldehyde and incubated for 15min at room 
temperature. Chromatin-Immunoprecipitation was 
conducted as described previously using 2µg anti c-Myc 
(clone N-262, Santacruz), 2µg anti acH3 (clone 06-599, 
Millipore), 2µg αIgG control (ab46540, abcam) antibodies. 
A detailed protocol is presented in the “supplemental 
Material and Methods section”.
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Case selection and classification for 
immunohistochemistry
127 B-cell lymphoma samples were obtained from the 
files of the lymph node registry Kiel with ethical approval 
andclassified according to the WHO classification using 
standard histological, immunohistochemical and molecular 
criteria [64]. In addition, 20 specimens obtained within the 
framework of the network project “Molecular Mechanisms in 
malignant Lymphoma” (MMML) were analysed. The latter 
cohort was diagnosed and classified based on the previously 
reported molecular signatures [30]. All lymphomas were 
analysed using tissue-micro-arrays (TMA) containing 2 cores 
of 1 mm or 0.6 mm (for the MMML specimen) for each case 
(ethical approval Ref. Nr. 1/1/05).
Bioinformatic analyses and analysed datasets
The identification of pathway activation clusters 
was performed using the Guided Clustering algorithm 
[28]. Guided Clustering identifies genes specific for one 
of the five stromal stimuli (BCR, CD40L, BAFF, IL-
21, LPS). Within this framework the stimulated BL2 
cells act as guiding data whereas the cohort of Myc-
negative DLBCL represent the guided dataset [30]. The 
definition of the required binary vector depends on the 
respective stimulation with the numerical value 1 for 
the stimulus and 0 for the remaining stimuli as well as 
for the controls. For each stimulation two clusters were 
extracted, showing an opposite regulation. The respective 
genes in each cluster may represent a potential surrogate 
marker for pathway activity in lymphoma samples. To 
determine the extent of gene cluster activity in lymphoma 
patients, one index was calculated by gene cluster and 
per lymphoma sample. Expression values from those 
genes assembling the individual cluster were used to 
calculate a single representative value (the index) for 
each sample by fitting a standard additive model with 
independent gene and sample effects using Tukey’s 
median polish procedure as described [65]. The index 
values of genes inhibited by a stimulus (.1 modules (eg 
BCR.1)) were multiplied by minus one to enable the 
interpretation of the indices as absence or presence of 
stimulation. Hence, down-regulation of these genes leads 
to a high index value (stimulation is present) whereas a 
low index value indicates the absence of any regulatory 
effect due to stimulation. Gene set enrichment analysis 
(GSEA) of ranked gene list was performed using the 
Java implementation of GSEA obtained from http://www.
broadinstitute.org/gsea/. GSEA was conducted in the 
mode for pre-ranked gene lists on the C2 set of curated 
gene signatures from the Molecular Signature Database 
(MSigDB). Genes are attributed to one ore more biological 
processes, molecular function and cellular location with 
respect to the Gene Ontology as well as pathways in the 
KEGG database [66, 67]. Hypergeometric testing was 
performed to test for non-random overrepresentation 
of module genes in each of these terms based on the 
hypergeometric distribution model. This GO/KEGG 
analyses was implemented in customized inhouse scripts.
The primary data are available from GEO (http://
www.ncbi.nlm.nih.gov/geo/) - raw data for gene 
expression changes for LPS, CD40L, BAFF, IL-21 
and αIgM stimulated BL2 cells are available under 
accession no. GSE42660 and GSE29700 [28, 32], 
data for CD10+ human tonsillar B cells (GSE71724), 
pathway inhibition (GSE68761) and gene expression 
kinetics (GSE71721) are summarized as SuperSeries 
record GSE71725.
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